tailieunhanh - báo cáo khoa học: "Phase 2 study of canfosfamide in combination with pegylated liposomal doxorubicin in platinum and paclitaxel refractory or resistant epithelial ovarian cancer"

Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài:Phase 2 study of canfosfamide in combination with pegylated liposomal doxorubicin in platinum and paclitaxel refractory or resistant epithelial ovarian cancer | Kavanagh et al. Journal of Hematology Oncology 2010 3 9 http content 3 1 9 JOURNAL OF HEMATOLOGY ONCOLOGY RESEARCH Open Access Phase 2 study of canfosfamide in combination with pegylated liposomal doxorubicin in platinum and paclitaxel refractory or resistant epithelial ovarian cancer 1 1 1 1 1 2 John J Kavanagh Charles F Levenback Pedro T Ramirez Judith L Wolf Carla L Moore Marsha R Jones Lisa Meng 2 Gail L Brown2 Robert C Bast Jr1 Abstract Background Canfosfamide is a novel glutathione analog activated by glutathione S-transferase P1-1. This study evaluated the safety and efficacy of canfosfamide in combination with pegylated liposomal doxorubicin PLD in patients with platinum resistant ovarian cancer. Patients with platinum resistant ovarian carcinoma and measurable disease received canfosfamide at 960 mg m2 in combination with PLD at 50 mg m2 intravenously day 1 in every 28 day cycles until tumor progression or unacceptable toxicities. The primary endpoints were objective response rate ORR and progression-free survival PFS . Results Canfosfamide plus PLD combination therapy was administered at 960 50 mg m2 respectively. Thirty-nine patients received a median number of 4 cycles range . The ORR was 95 CI with a disease stabilization rate of 95 CI in the evaluable population. The CA-125 marker responses correlated with the radiological findings of complete response or partial response. The median PFS was months 95 CI and median survival was months. The combination was well tolerated. Myelosuppression was managed with dose reductions and growth factor support. Grade 3 febrile neutropenia was observed in 2 patients . Non-hematologic adverse events occurred at the expected frequency and grade for each drug alone with no unexpected or cumulative toxicities. Conclusions Canfosfamide in combination with PLD is well tolerated and active in platinum and paclitaxel refractory or resistant ovarian